world
Hong Kong Researchers Present Preclinical Data on GLP-1 Agonists in Stroke Models Combined with Thrombectomy
Chinese University of Hong Kong researchers reported that GLP-1 weight-loss drugs, administered before and after thrombectomy, can offer neuroprotective effects for ischemic stroke patients who miss the window for intravenous thrombolysis. The team linked the potential benefit to the pathway's anti-ageing properties. Ischemic strokes account for 80 per cent of all stroke cases globally.
May 14, 6:45 PM·2m read1 source
SC
info.gov.hkAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Chinese University of Hong Kong scientists stated on Thursday that Chinese University of Hong Kong scientists have presented preclinical findings suggesting that GLP-1 receptor agonists may have neuroprotective effects in ischemic stroke models when combined with mechanical thrombectomy.
Administering a GLP-1 injection before and after a thrombectomy produced measurable improvements in neurological scores in preclinical models, equivalent to up to a 20% gain on the scales used. if they missed the window for an intravenous thrombolysis, the scientists said.
Ischemic strokes account for 80 per cent of all stroke cases globally and are caused by the obstruction of blood vessels supplying blood to the brain.
Dr Ko Ho, director of the Gerald Choa Neuroscience Institute and an associate professor of CU Medicine, said the team made the discovery while pursuing effective interventions targeting ageing-related biological changes. The scientists made the statement on Thursday, according to @SCMPNews reported. “Our team began prioritising the GLP-1 signalling pathway about seven or eight years ago.
GLP-1 is a ‘superstar’ pathway in biological, medical and pharmaceutical fields, primarily due to its success in treating type 2 diabetes and obesity,” Dr Ko Ho said. GLP-1 drugs, or glucagon-like peptide-1 receptor agonists, are a class of prescription medications that mimic a natural gut hormone to regulate blood sugar and suppress appetite.
Dr Ko Ho said clinical data previously indicated that beyond lowering blood sugar and reducing weight, GLP-1 appeared to offer additional benefits that could not be explained at that time.
